US 4,071,619 A · Method of producing vaccines

Method of producing vaccines

OwnerTamaz Vladimirovich Peradze, Eidlya Abramovna Fridman +7inventors

InventorsTamaz Vladimirovich Peradze, Eidlya Abramovna Fridman, Nina Vsevolodovna Zheleznova, Vsevolod Mikhailovich Kolikov, Semen Khaimovich-Efimovich Bresler, Boris Viktorovich Mchedlishvili, Viktor Mikhailovich Molodkin, Ljudmila Mikhailovna Molodkina, Nina Vasilievna Katushkina

Life of this patent

Estimating the term…

Abstract

A method for producing vaccines wherein a suspension of the viral culture is purified by gel chromatography in a column packed with a porous virion non-sorbing silicate material having pore diameter of 50 to 10000 A, followed by adsorption-elution concentration and completion of the vaccine, or the starting suspension of the viral culture is concentrated by adsorption-elution and then purified by gel chromatography in a column packed with porous silicate material having pore diameter of 50 to 10000 A, or the starting suspension of the viral culture is subjected to gel chromatography in a column filled with a porous silicate material having pore diameter of 50 to 10000 A and the final vaccine is produced.

Claims8

Dependent claims

A method for producing vaccines comprising purification of a viral culture by gel chromatography in columns packed with a porous silicate virion non-absorbing material having pore diameter of 50 to 10,000A, concentration by adsorption in columns packed with a porous silicate sorbent having a pore diameter of 50 to 10,000A and a porosity of 0.3 to 2.5 cm.sup.3 /g, followed by virus desorption by means of buffer solutions having a pH of 6 to 10 in two steps using a gradient of ionic strength of from 0.1 to 1.0:

a. at the beginning of the gradient, the columns are washed to eliminate the initial culture remaining between the sorbent granules, and
b. at the end of the gradient, virions are desorbed, with subsequent transfer of the viral suspension into physiological conditions of pH 7 to 7.8 with NaCl concentration of 0.14-0.15 mole/1 and inactivation of the viral suspension.

Dependencies are inferred from the claim text.